Malignant pleural mesothelioma: utility of 18 F-FDG PET.

Détails

ID Serval
serval:BIB_7BC69694525B
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Malignant pleural mesothelioma: utility of 18 F-FDG PET.
Périodique
Annali italiani di chirurgia
Auteur(s)
Spitilli M.G., Treglia G., Calcagni M.L., Giordano A.
ISSN
0003-469X (Print)
ISSN-L
0003-469X
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
78
Numéro
5
Pages
393-396
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Malignant Pleural Mesothelioma is a rare tumour that arise from the mesothelial cells of the pleura and in recent time the incidence of this disease is rising. Because of the implications for management and therapy, it is important to assess the accurate staging. 18F-fluorodeoxiglucose Positron Emission Tomography (18F-FDG PET) is become a useful tool in the diagnosis of many neoplasms, such as Malignant Pleural Mesothelioma. In particular it has been shown to be useful in the evaluation of the extent of pleural disease, in the establishment of lymph node involvement, in the evaluation of tumour invasion into the lung and thoracic wall, in the diagnosis of extrathoracic metastases, in the assessment of the response to treatment, and in planning radiotherapy. Developments in system technology, like improvements in hybrid system (integrated Positron Emission Tomography/Computed Tomography) and the discovery of new radiopharmaceuticals, promise to make PET much more useful and versatile in the future.

Mots-clé
Fluorodeoxyglucose F18, Humans, Mesothelioma/diagnostic imaging, Pleural Neoplasms/diagnostic imaging, Positron-Emission Tomography, Radiopharmaceuticals
Pubmed
Création de la notice
20/08/2017 22:23
Dernière modification de la notice
03/03/2018 18:36
Données d'usage